Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab plus erlotinib was compared to erlotinib plus placebo in patients with EGFR-mutated non–small cell lung cancer. These data were presented at the 2019 ASCO Annual Meeting.
Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab (Cyramza) plus erlotinib (Tarceva) was compared to erlotinib plus placebo in patients with EGFR-mutated non–small cell lung cancer (NSCLC). These data were presented at the 2019 ASCO Annual Meeting.
Overall, the median progression-free survival (PFS) was 19.4 months by investigator assessment in the ramucirumab/erlotinib arm versus 12.4 months in the erlotinib-alone arm (HR, 0.591; 95% CI, 0.461-0.760; P <.0001). Garassino says it is still early for the overall survival data as they have not yet matured, but the results suggest that the PFS2 is longer in the combination arm as well. She also notes that the toxicity profile was manageable with the combination regimen.
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More